← Back to Search

Glucagon-like peptide-1 receptor agonist

Semaglutide for Obesity (STABLE Wt Loss Trial)

Phase 4
Waitlist Available
Research Sponsored by University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Aged 18-70 years
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up s1: change from baseline to weeks 20, 40, and 60, and measures at week 72; s2: week 72 endpoint controlling for s1 baseline
Awards & highlights

STABLE Wt Loss Trial Summary

This trial will study the effects of semaglutide, a weight-loss medication, on eating behavior and appetite. All participants will receive diet and exercise counseling, and will be prescribed semaglutide or placebo for 72 weeks.

Who is the study for?
Adults aged 18-70 wanting to lose weight, with a BMI ≥ 30 or ≥ 27 with obesity-related health issues. Must not be pregnant, able to consent, and plan to stay in Philadelphia for the study duration. Excludes those with uncontrolled diabetes or hypertension, recent pancreatitis or cancer history, severe psychiatric disorders, recent weight loss drugs use, and certain cardiovascular conditions.Check my eligibility
What is being tested?
The trial tests if semaglutide affects appetite and eating habits over time compared to a placebo. Participants also receive lifestyle advice on diet and exercise. Semaglutide is an FDA-approved medication for weight loss administered subcutaneously for 72 weeks alongside behavioral treatment.See study design
What are the potential side effects?
Semaglutide may cause digestive issues like nausea or constipation, headaches, fatigue, risk of low blood sugar levels (hypoglycemia), potential thyroid tumors (rare), gallbladder problems like gallstones, inflammation of the pancreas (pancreatitis), and possible allergic reactions.

STABLE Wt Loss Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 70 years old.

STABLE Wt Loss Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~s1: change from baseline to weeks 20, 40, and 60, and measures at week 72; s2: week 72 endpoint controlling for s1 baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and s1: change from baseline to weeks 20, 40, and 60, and measures at week 72; s2: week 72 endpoint controlling for s1 baseline for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Ad libitum energy intake (kcal) during a buffet lunch meal (4 hrs after standardized breakfast)
Secondary outcome measures
Explicit responsiveness to the food environment measured by the summary score of the Power of Food Scale (15-item version)
Global subjective appetite (e.g., hunger, fullness, food preoccupation) over the past week measured using the Control of Eating Questionnaire (COEQ)
Implicit food wanting of high-fat, savory foods measured using the Leeds Food Preference Task
+1 more
Other outcome measures
Body image satisfaction (Body Satisfaction Scale)
Body weight (kg)
Drive for thinness (Eating Disorder Inventory [EDI])
+11 more

STABLE Wt Loss Trial Design

2Treatment groups
Active Control
Group I: Behavioral Treatment + PlaceboActive Control2 Interventions
Behavioral treatment (lifestyle modification counseling for weight loss) plus placebo
Group II: Behavioral Treatment + MedicationActive Control2 Interventions
Behavioral treatment (lifestyle modification counseling for weight loss) plus semaglutide

Who is running the clinical trial?

University of PennsylvaniaLead Sponsor
2,016 Previous Clinical Trials
42,873,976 Total Patients Enrolled
89 Trials studying Obesity
77,417 Patients Enrolled for Obesity
Novo Nordisk A/SIndustry Sponsor
1,520 Previous Clinical Trials
2,416,261 Total Patients Enrolled
143 Trials studying Obesity
132,263 Patients Enrolled for Obesity

Media Library

Obesity Research Study Groups: Behavioral Treatment + Placebo, Behavioral Treatment + Medication
~45 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top